

BONESUPPORT – Publication of a clinical study highlighting Vancomycin release from CERAMENT® V in major hip surgery

Lund, Sweden, 08.00 CET, 22 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of new data on antibiotic release from CERAMENT® V in a clinical study. The study ‘Vancomycin elution from a biphasic ceramic bone substitute’ is published in *Bone Joint Research* (*Bone Joint Res 2019; 8: 1-6*).

Prof. Lars Lidgren from Lund University, senior author of the publication, commented: “This study represents an important milestone in understanding the antibiotic excretion kinetics of CERAMENT V in patients undergoing major hip surgery. The pharmacokinetic analyses showed initial high targeted local vancomycin levels, safe and low systemic levels and sustained and complete release from the ceramic bone substitute at one month”.

Prof. Sarunas Tarasevicius from the Lithuanian University of Health, Kaunas said “This is the first long-term pharmacokinetic report on vancomycin release from injectable CERAMENT V. It has already previously been proven that the plain ceramic bone graft substitute regenerates bone. The results of the study confirm that by combining initial high local antibiotic release with sustainable levels for a sufficient time, the bone graft substitute should also be useful to eradicate and prevent bone infection”.

University of Lund performed the research in collaboration with M. Stravinskas, A. Vitkauskien and S. Tarasevicius from the Lithuanian University of Health at Kaunas, Lithuania.

The publication can be found in *Bone Joint Res 2019; 8: 1-6*:

<https://online.boneandjoint.org.uk/doi/10.1302/2046-3758.82.BJR-2018-0174.R2>

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks.

Press Release

For more information contact:

BONESUPPORT AB

Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46(0) 46 286 53 70
ir@bonesupport.com

Cord Communications

Charlotte Stjerngren
+46 (0)708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se